Brickell Biotech Stock Short Ratio
BBIDelisted Stock | USD 1.79 0.34 23.45% |
Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.
Brickell |
Brickell Biotech Company Short Ratio Analysis
Brickell Biotech's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Current Brickell Biotech Short Ratio | 0.62 X |
Most of Brickell Biotech's fundamental indicators, such as Short Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
CompetitionBased on the latest financial disclosure, Brickell Biotech has a Short Ratio of 0.62 times. This is 84.1% lower than that of the Biotechnology sector and 91.63% lower than that of the Health Care industry. The short ratio for all United States stocks is 84.5% higher than that of the company.
Brickell Short Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brickell Biotech's direct or indirect competition against its Short Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brickell Biotech could also be used in its relative valuation, which is a method of valuing Brickell Biotech by comparing valuation metrics of similar companies.Brickell Biotech is currently under evaluation in short ratio category among its peers.
Brickell Fundamentals
Return On Equity | -1.57 | |||
Return On Asset | -0.8 | |||
Operating Margin | (6.58) % | |||
Current Valuation | (8.35 M) | |||
Shares Outstanding | 2.87 M | |||
Shares Owned By Insiders | 1.20 % | |||
Shares Owned By Institutions | 13.07 % | |||
Number Of Shares Shorted | 189.59 K | |||
Price To Earning | (35.16) X | |||
Price To Book | 0.41 X | |||
Price To Sales | 1.45 X | |||
Revenue | 404 K | |||
Gross Profit | (27.83 M) | |||
EBITDA | (39.38 M) | |||
Net Income | (39.47 M) | |||
Cash And Equivalents | 17.29 M | |||
Cash Per Share | 6.52 X | |||
Total Debt | 69 K | |||
Debt To Equity | 0 % | |||
Current Ratio | 4.36 X | |||
Book Value Per Share | 5.81 X | |||
Cash Flow From Operations | (36.15 M) | |||
Short Ratio | 0.62 X | |||
Earnings Per Share | (0.42) X | |||
Target Price | 17.83 | |||
Number Of Employees | 16 | |||
Beta | 0.0796 | |||
Market Capitalization | 6.75 M | |||
Total Asset | 29.72 M | |||
Retained Earnings | (145.37 M) | |||
Working Capital | 24.79 M | |||
Current Asset | 52.66 M | |||
Current Liabilities | 5.61 M | |||
Net Asset | 29.72 M |
About Brickell Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Brickell Stock
If you are still planning to invest in Brickell Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Brickell Biotech's history and understand the potential risks before investing.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |